Navigation Links
Abbott's XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
Date:9/21/2009

entation, subgroup analyses from the SPIRIT III trial demonstrated evidence of the strong performance by XIENCE V in a variety of patients and lesion types that represent complex patients. In patients with diabetes, the analysis showed there was no difference at three years in MACE between XIENCE V and TAXUS (11.0 percent for XIENCE V vs. 10.3 percent in TAXUS)*** . In fact, XIENCE V maintained a consistent rate of clinical events after the first year (8.7 percent MACE at one year and 11.0 percent MACE at three years), whereas TAXUS demonstrated a sustained upward trend in clinical events from one year to three years (4.7 percent MACE at one year and 10.3 percent MACE at three years). In patients without diabetes, the MACE rate for TAXUS at three years was more than double the MACE rate for XIENCE V at three years (9.1 percent for XIENCE V vs. 18.7 percent for TAXUS).

"The SPIRIT III data clearly show that XIENCE V performs in a consistent manner, with clinical benefits continuing to improve over time compared to TAXUS," said Robert Hance, senior vice president, vascular, Abbott. "We are pleased to begin this year's TCT conference with a strong showing of data for Abbott's market-leading XIENCE V, and look forward to presenting the highly anticipated SPIRIT IV one-year results later this week, which should provide physicians with additional valuable insights."

One-year results from the company's SPIRIT IV trial will be presented on Wednesday, Sept. 23, during the first late-breaking clinical trials session of the TCT conference. The SPIRIT IV trial is one of the largest randomized clinical trials between two drug eluting stents, with 3,690 patients enrolled, including more than 1,000 patients with diabetes. The study results will provide valuable information about the efficacy and safety of XIENCE V compared to TAXUS. The SPIRIT III trial was not designed to analyze statistical differences in any of the patient subgroups, as th
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
2. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
3. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
4. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
5. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
6. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
7. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
8. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
9. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
10. Clinical Genomics Continues Progress in Developing Biomarker Portfolio for Colorectal Cancer Testing
11. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014  Georgia-Pacific Professional is ... and tissue for a wide range of away ... its product lines in healthcare, including hospitals, long-term ... Professional is introducing its healthcare products and solutions ... understands the importance of infection control in the ...
(Date:9/30/2014)... BURLINGTON, Mass. , Sept. 30, 2014 /PRNewswire/ ... of U.S. patient-level claims data, anemic chronic kidney ... with their erythropoiesis-stimulating agent (ESA) medication. In addition, ... Janssen,s Procrit. Other key findings ... in Nephrology: An Analysis of Erythropoiesis Stimulating Agents ...
(Date:9/30/2014)... 30, 2014   Acutus Medical, Inc. ... real-time 3D Cardiac Chamber Imaging and Dipole Density Mapping ... or sustain complex cardiac arrhythmias, including atrial fibrillation, announced ... developing its imaging/mapping system as well as bring to ... Acutus Medical to complete work on the AcQMap TM ...
Breaking Medicine Technology:Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 3Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 2Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 3
... Inc. (OTCBB: PLCSF), a company focused on innovative medical ... REMEDIAL II investigator-sponsored clinical trial of RenalGuard® ... , a peer-reviewed journal of the American Heart Association ... in the September 2011 issue of the publication.  The ...
... A national analysis conducted by Sperling,s BestPlaces and ... Columbus, Ohio, as one of the nation,s Hypertension ... factors and complications. The identification of the Hypertension ... hypertension awareness program called Commit to Control ...
Cached Medicine Technology:REMEDIAL II Trial of PLC's RenalGuard® Article Published in Circulation 2REMEDIAL II Trial of PLC's RenalGuard® Article Published in Circulation 3REMEDIAL II Trial of PLC's RenalGuard® Article Published in Circulation 4Columbus Included in Analysis of Top Hypertension Hot Spots in the United States 2Columbus Included in Analysis of Top Hypertension Hot Spots in the United States 3Columbus Included in Analysis of Top Hypertension Hot Spots in the United States 4
(Date:9/30/2014)... Integrated Medicine Alliance , Monmouth ... new medical specialty practice through a unique partnership with ... be located within the company’s Shrewsbury location and will ... Tawfik of American Heart Center, P.C., a highly regarded ... offer Integrated Medicine Alliance patients top notch cardiovascular care ...
(Date:9/30/2014)... 30, 2014(BRONX, NY)Medications are the leading cause of allergy-related ... of death certificates from 1999 to 2010, conducted by ... Albert Einstein College of Medicine of Yeshiva University ... Journal of Allergy and Clinical Immunology , also found ... particularly high among older people and African-Americans and that ...
(Date:9/30/2014)... 2014 EverStryke , the permanent match ... SurvivalLife.com along with a free book and class all about ... Michaels, prompting an investigative review. , “Joe Marshall of ... survival and preparation niche, and this product is an excellent ... and survival products that Joe offers on his website to ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 The ... option to help diabetics curb their sweet tooth, but ... Nature this September, suggests that zero-calorie sweeteners may ... 2 diabetes. , The Weizmann Institute of Science ... fed artificial sweeteners to mice, the mice developed glucose ...
(Date:9/30/2014)... 30, 2014 Hospice & Palliative ... “In Celebration” gala, honoring three outstanding individuals for ... striving to provide extraordinary and dignified comfort, care ... serious or life-limiting illness. , The event was ... NY and recognized William (Bill) J. McGuinness, Director ...
Breaking Medicine News(10 mins):Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:Comprehensive Study of allergic deaths in US finds medications are main culprit 2Health News:EverStryke: Review Exposes Joe Marshall’s Permanent Match Survival Product 2Health News:Artificial Sweeteners May be Linked to Greater Diabetes Risk 2Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2
... President of ... the Lyme Disease Association., JACKSON, N.J., Oct. 4 The ... "A Clinical Appraisal,of ,Chronic Lyme Disease.," Eleven of its authors also ... by the,Connecticut Attorney General for the development of those Guidelines.,Although the ...
... to stress the disease,s link to heart disease , , THURSDAY, Oct. ... pretty. , An acclaimed rock musician and record producer, he was ... Fox television,s soon-to-be monster hit American Idol . , Then ... diabetes. , Today, with his disease under control, Jackson wants to ...
... technological know how to patient care were demonstrated by ... , Imperials Rector, Sir Richard Sykes, and Professor of ... Darzi, took the PM on a tour of the ... The Institute is at the forefront of medical innovation, ...
... Nastech Pharmaceutical,Company Inc. (Nasdaq: NSTK ) ... to Chief Scientific Officer of Delivery. Dr. Costantino,will ... new,drug delivery technologies for peptide and protein therapeutics. ... is retiring,tomorrow, October 5, 2007, as was previously ...
... Oct. 4 /PRNewswire-FirstCall/ - CRH Medical Corporation,(CRM: TSX-V) ... the American,College of Surgeons 93rd Annual Clinical Congress ... CRH will be focused on recruiting General ... its number of Centers for,Colorectal Health. Commenting ...
... Series, new rules for the first time forced players to ... and coaches had to strategize how pitchers were used more ... 12 and under could throw up to six innings per ... an increase in reported cases of young pitchers experiencing arm ...
Cached Medicine News:Health News:NEJM Owes Patients Responsible Journalism, Says Lyme Disease Association 2Health News:Randy Jackson Takes Aim at Diabetes 2Health News:Randy Jackson Takes Aim at Diabetes 3Health News:Prime Minister views innovative health technology at Imperial College London 2Health News:Nastech Pharmaceutical Company Announces Promotion of Rick Costantino, Ph.D., to Chief Scientific Officer of Delivery 2Health News:Nastech Pharmaceutical Company Announces Promotion of Rick Costantino, Ph.D., to Chief Scientific Officer of Delivery 3Health News:CRH Medical to exhibit at American College of Surgeons Annual Clinical Congress 2Health News:How pitching changes little leaguers' shoulders 2Health News:How pitching changes little leaguers' shoulders 3
... 2 60-ms bursts of 50 Hz separated by .75 ... Tetanus: 50 Hz (50 pulses/s) or 100 Hz (100 ... Output Current: Adjustable from 0-70 mA , Stimulus ... Battery LED (green) indicates that the units on; it ...
Anesthesia Associates Nerve Stimulator Model AA 1050...
... newest peripheral nerve stimulator from B. Braun Medical. ... providing advanced digital technology. , ,Your ability ... allows the localization of practically all mixed nerves ... ,An additional optional component for the HNS11 is ...
... original MS-III design the new ... keypad and battery ... MS-IV peripheral nerve stimulator can ... in operating room, post anesthesia ...
Medicine Products: